MX2023009091A - Composiciones oftalmologicas topicas. - Google Patents

Composiciones oftalmologicas topicas.

Info

Publication number
MX2023009091A
MX2023009091A MX2023009091A MX2023009091A MX2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A
Authority
MX
Mexico
Prior art keywords
ophthalmic composition
topical ophthalmological
ophthalmological compositions
topical ophthalmic
topical
Prior art date
Application number
MX2023009091A
Other languages
English (en)
Spanish (es)
Inventor
Rong Yang
Jinsong Ni
Van Dinh
Original Assignee
Ads Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ads Therapeutics Llc filed Critical Ads Therapeutics Llc
Publication of MX2023009091A publication Critical patent/MX2023009091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023009091A 2021-02-03 2022-02-02 Composiciones oftalmologicas topicas. MX2023009091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163145091P 2021-02-03 2021-02-03
PCT/US2022/014811 WO2022169788A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Publications (1)

Publication Number Publication Date
MX2023009091A true MX2023009091A (es) 2023-08-09

Family

ID=82741579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009091A MX2023009091A (es) 2021-02-03 2022-02-02 Composiciones oftalmologicas topicas.

Country Status (8)

Country Link
US (3) US12070501B1 (cg-RX-API-DMAC10.html)
EP (1) EP4288151A4 (cg-RX-API-DMAC10.html)
JP (2) JP7749020B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230142548A (cg-RX-API-DMAC10.html)
AU (1) AU2022217160A1 (cg-RX-API-DMAC10.html)
CA (1) CA3206612A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009091A (cg-RX-API-DMAC10.html)
WO (1) WO2022169788A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
WO2025131038A1 (en) * 2023-12-21 2025-06-26 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2026003129A1 (en) * 2024-06-26 2026-01-02 Novaliq Gmbh Stabilization of (r)-ruxolitinib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE10030378A1 (de) 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
US20100323978A1 (en) * 2009-06-22 2010-12-23 Calvin Hanna Non-aqueous oil delivery system for ophthalmic drugs
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
CN109803650A (zh) 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
EP3585386A4 (en) 2017-02-21 2020-12-30 Singapore Health Services PTE Ltd COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE
EP3638643B1 (en) 2017-06-12 2023-01-18 Novaliq GmbH Process for the preparation of semifluorinated alkanes using grignard reagents
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
AU2020216470B2 (en) * 2019-02-01 2023-05-04 Alcon Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Also Published As

Publication number Publication date
EP4288151A4 (en) 2025-01-01
US20260124305A1 (en) 2026-05-07
KR20230142548A (ko) 2023-10-11
JP2025176201A (ja) 2025-12-03
US20250000980A1 (en) 2025-01-02
EP4288151A1 (en) 2023-12-13
CA3206612A1 (en) 2022-08-11
JP7749020B2 (ja) 2025-10-03
JP2024511695A (ja) 2024-03-15
WO2022169788A1 (en) 2022-08-11
US12485177B2 (en) 2025-12-02
AU2022217160A1 (en) 2023-08-17
AU2022217160A9 (en) 2025-01-30
US12070501B1 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
BR112023006371A2 (pt) Composição oftalmológica tópica
Steven et al. Preservatives in glaucoma medication
Aguayo Bonniard et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CY1125495T1 (el) Φαρμακευτικη συνθεση αποτελουμενη αποτιβοζανιμπη
Realini et al. Low-energy selective laser trabeculoplasty repeated annually: rationale for the COAST trial
MX2025000595A (es) Compuestos de heteroarilo como degradadores de cinasa 4 asociada al receptor de interleucina 1 (irak4) dirigidos por ligando
CL2011000378A1 (es) Uso de edta asociado a trometamina o sales de edta oftalmologicamente aceptables asociadas a trometamina, y/o uno o mas fotointensificadores escogidos entre; amarillo de acridina, amarillo de quinidina, azul de metileno, eritrosina; composicion oftalmologica.
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
AR062046A1 (es) Soluciones oftalmicas
UY28709A1 (es) Derivados de prostaglandinas
BR112012033111A2 (pt) método e aparelho para integrar cirurgia de catarata à cirurgia de glaucoma ou astigmatismo
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
CL2020002619A1 (es) Composiciones plaguicidas de aceites naturales mejoradas
PA8806901A1 (es) Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
FI3723739T3 (fi) Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi
ES2722723T3 (es) Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
US20180021327A1 (en) Treatment of corneal neovascularization
CO2024014485A2 (es) Compuestos heterociclicos moduladores de bcl6 como degradadores dirigidos por ligando
Banitt et al. Ocular surface disease in the glaucoma patient
MX391657B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular